E-ISSN: 1305-3612
Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors
PDF
Cite
Share
Request
Interventional Radiology - Original Article
VOLUME: 26 ISSUE: 2
P: 111-117
March 2020

Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors

Diagn Interv Radiol 2020;26(2):111-117
DOI: 10.5152/dir.2019.19246
Dong Kyu Kim
Kichang Han
Jong Yun Won
Gyoung Min Kim
Joon Ho Kwon
Man Deuk Kim
1. Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University School of Medicine, Seoul, Korea
No information available.
No information available
Received Date: 13.05.2019
Accepted Date: 07.08.2019
PDF
Cite
Share
Request

ABSTRACT

PURPOSE

We aimed to evaluate the effectiveness and safety of percutaneous cryoablation (PC) for early or very early stage hepatocellular carcinoma (HCC) and assess the risk factors for local tumor progression (LTP) after PC.

METHODS

A total of 45 treatment-naïve patients treated with PC for early or very early stage HCCs were included in this retrospective study. The safety of PC was assessed by evaluating procedure-related complications and comparing hepatic function before and after the procedure. The effectiveness was assessed by evaluating technical success, LTP rates, and disease progression (DP) rates. Prognostic factors associated with LTP after PC were also analyzed.

RESULTS

Technical success and complete response were achieved in all patients (100%) by 1 month after PC. During a mean of 28.1±15.6 months of follow-up, the incidences of LTP and DP were 11.1% and 37.8%, respectively. The LTP-free and DP-free survival rates were 93.3% and 84.4% at 1 year and 88.9% and 62.2% at 2 years, respectively. Hepatic function was normalized within 3 months after PC. There were no major complications and only one minor complication of small hematoma. On univariate and multivariate analysis, minimal ablative margin <5 mm was the only significant risk factor associated with LTP.

CONCLUSION

PC is a safe and effective therapy for patients with early or very early stage HCC. Minimal ablative margin <5 mm was a significant prognostic factor for LTP.